DOCSLIB.ORG

Outputs, Outcomes and Impact of MRC Research 2014/15 Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Outputs, Outcomes and Impact of MRC Research 2014/15 Report Outputs, outcomes and impact of MRC research 2014/15 report European Union (EU) Scale: 1 Collaboration ISBN 978-0-903730-22-8 © Medical Research Council copyright 2016 You may re-use this information (excluding logos, images and icons) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit http://www.nationalarchives.gov.uk/doc/open-government-licence/ or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or e-mail: [email protected] When providing a citation for this document we recommend the following: Medical Research Council (2016) MRC Outputs, outcomes and impact of MRC research 2014/15 report. Publisher: Medical Research Council, London, UK. ISBN: 978-0-903730-22-8 Any enquiries related to this publication should be sent to us at: Medical Research Council, 14th Floor, One Kemble Street, London WC2B 4AN or [email protected] This publication is available at https://www.mrc.ac.uk/successes/outputs-report/ Table of Contents List of case studies by primary output type 3 SECTION 1.0: Introduction 7 Overview 9 Key 11 researchfish® 12 SECTION 2.0: Case studies 15 2.1: Published research 17 2.2: Policy and engagement 37 2.3: Development of products and intellectual property 65 2.4: Research materials 107 2.5: Industry interactions and other collaborations 135 2.6: Awards and recognition 165 SECTION 3: Quantitative analysis 179 3.1 Publications 181 3.2: Collaborations 186 3.3 Further funding 191 3.4 Next destination 198 3.5 Engagement activities 201 3.6 Influence on policy 205 3.7 Research materials – tools and methods, databases and models 210 3.8 Intellectual property 215 3.9 Products and interventions 219 3.10 Awards and recognition 225 Front cover image credits Mosquito on human skin at sunset. Image credit: Shutterstock | Ebola workers in Liberia. Image credit: Flickr/European Commission DG ECHO CC BY 3.0 | An image from the BoneFinder software. Image credit: Claudia Lindner, University of Manchester | Back of the eye showing intermediate age-related macular degeneration. Image credit: National Eye Institute, National Institutes of Health | Bacteriophage. Image credit: BlueSci. Cambridge University science magazine | Niall Kent. Image credit: Niall Kent, UCL Outputs, outcomes and impact of MRC research: 2014/15 report 1 2 Outputs, outcomes and impact of MRC research: 2014/15 report List of case studies by primary output type Publications » Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. page 24 » MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial ....................................page 25 » An integrated map of genetic variation from 1,092 human genomes ..................................page 25 » Clinical and biomarker changes in dominantly inherited Alzheimer’s disease ............................page 26 » Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. .page 27 » A molecular marker of artemisinin-resistant Plasmodium falciparum malaria ...........................page 27 » Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis ..............................................................page 28 » Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci ......................................................page 29 Collaborations » NeuroStemCell ...................................................................................page 141 » Uncovering how fever stimulates HIV replication ....................................................page 150 » Drug safety .......................................................................................page 151 » Smartphone app to monitor musculoskeletal disease ................................................page 153 » Developing drugs to treat liver fibrosis ..............................................................page 154 » Mechanisms in fatty liver disease ..................................................................page 155 » Thrombolytic treatment soon after stroke reduces risk of disability. .page 156 » Medicines for Malaria Venture .....................................................................page 158 » The Clinical Trials Transformation Initiative (CTTI) ...................................................page 159 Further funding » Bacteria-eating viruses ............................................................................page 143 » Developing treatments for and harnessing the potential of Clostridia .................................page 143 » Epigenetics in Alzheimer’s disease ..................................................................page 147 » Understanding the immune response in Crohn’s disease .............................................page 149 » Economic evaluation of healthcare technologies ....................................................page 153 Outputs, outcomes and impact of MRC research: 2014/15 report 3 Engagement activities » Functional genome ................................................................................page 43 » Antimicrobial resistance media coverage ............................................................page 47 » Edinburgh Fringe Festival. page 49 » Muscular Dystrophy Campaign (MDC) Duchenne and Becker impact day ..............................page 50 » The secret life of four-year olds .....................................................................page 51 » Role of the habenula in negativity ...................................................................page 52 » Expert commentary on healthy diet. page 54 » Alcohol consumption in pregnancy .................................................................page 55 Influence on policy » Reports on Ebola to the World Health Organization and other international stakeholders ...............page 40 » International rabies strategies ......................................................................page 41 » Setting WHO post-2015 global tuberculosis targets ...................................................page 42 » NICE guidelines on Hypertension: Clinical management of primary hypertension in adults ..............page 44 » American Heart Association guidelines for arteriovenous malformations of the brain ...................page 45 » NICE guidelines on Eculizumab for treating atypical haemolytic uraemic syndrome (aHUS). .page 46 » Participation in Acting on Campylobacter Together (ACT) campaign ..................................page 48 » Co-author of 2014 Chief Medical Officer (CMO) annual report on public mental health .................page 51 » NICE guidelines on Managing overweight and obesity in adults – lifestyle weight management services. .page 52 » Citations in public health guidelines on physical activity ..............................................page 53 » Smoking reduction .................................................................................page 56 » Expert witness to Commission on Hearing Loss ......................................................page 57 Research tools and methods » Screening device to predict how patients will respond to leukaemia chemotherapy ...................page 111 » Genetically-modified cell line to repair damaged nerve ..............................................page 112 » Device to monitor antibiotic effectiveness .........................................................page 114 » Mice with deleted immune cells ...................................................................page 114 » Cell line to help investigate the regulation of an immune system process .............................page 115 » Eye tissue repository ..............................................................................page 116 » Mouse model with gene mutation affecting metabolism ............................................page 119 » MRI protocol to investigate brain health ............................................................page 120 » Brain and spinal cord tissue ........................................................................page 121 » Drosophila model of neurodegeneration ...........................................................page 122 » Detecting asymptomatic malaria infections .........................................................page 124 » Rabbit model of cryptococcal meningitis ...........................................................page 125 » Tools to detect genome-wide DNA damage and repair ..............................................page 126 » Simulation model for prostate cancer ..............................................................page 128 » Platform to predict effective drug combinations ....................................................page 129 4 Outputs, outcomes and impact of MRC research: 2014/15 report Research databases and models » Mathematical model of anti-virulence drugs to treat bacterial infections .............................page 113 » UK Primary Sjögren’s Syndrome Registry (UKPSSR) ..................................................page 115 » Database of HIV patients ..........................................................................page 118 » The Twins Early Development Study (TEDS) dataset .................................................page 123 » International Mouse Phenotyping
Load more

Recommended publications
  • Genomes of the T4-Related Bacteriophages As Windows on Microbial Genome Evolution
    Petrov et al. Virology Journal 2010, 7:292 http://www.virologyj.com/content/7/1/292 REVIEW Open Access Genomes of the T4-related bacteriophages as windows on microbial genome evolution Vasiliy M Petrov1, Swarnamala Ratnayaka1, James M Nolan2, Eric S Miller3, Jim D Karam1* Abstract The T4-related bacteriophages are a group of bacterial viruses that share morphological similarities and genetic homologies with the well-studied Escherichia coli phage T4, but that diverge from T4 and each other by a number of genetically determined characteristics including the bacterial hosts they infect, the sizes of their linear double- stranded (ds) DNA genomes and the predicted compositions of their proteomes. The genomes of about 40 of these phages have been sequenced and annotated over the last several years and are compared here in the con- text of the factors that have determined their diversity and the diversity of other microbial genomes in evolution. The genomes of the T4 relatives analyzed so far range in size between ~160,000 and ~250,000 base pairs (bp) and are mosaics of one another, consisting of clusters of homology between them that are interspersed with segments that vary considerably in genetic composition between the different phage lineages. Based on the known biologi- cal and biochemical properties of phage T4 and the proteins encoded by the T4 genome, the T4 relatives reviewed here are predicted to share a genetic core, or “Core Genome” that determines the structural design of their dsDNA chromosomes, their distinctive morphology and the process of their assembly into infectious agents (phage morphogenesis).
    [Show full text]
  • Symposium ”Diabetes - a Threat to Mankind”
    Symposium ”Diabetes - a Threat to Mankind” 7-8 June, 2013 in Helsinki, Finland The Finnish Diabetic Nephropathy Study Folkhälsan Institute of Genetics, Folkhälsan Research Center Biomedicum Helsinki 1, room C318 Haartmaninkatu 8 FI- 00290, Helsinki www.finndiane.fi Local Organizing Committee Per-Henrik Groop [email protected] tel. +358 9 191 25459 Carol Forsblom [email protected] tel. +358 40 5559556 Asta Mustonen [email protected] tel. +358 44 7883743 Maikki Parkkonen [email protected] tel. +358 9 19125387 Dear Participants, It is my great pleasure and honor to welcome you all to the “Diabetes – A Threat to Mankind” symposium held in Helsinki on June 7-8, 2013. This symposium will include presentations by a roster of award winning keynote speakers exploring both type 1 and type 2 diabetes and cover- ing topics ranging from disease pathogenesis to diabetic complications. This symposium was made possible by an unrestricted educational grant from the Wilhelm and Else Stockmann Foundation. Established in 1953 with the goal of promoting research that aims to prevent or ease the suffering caused by common complex diseases, the Wilhelm and Else Stockmann Foundation has played a major role in supporting dia- betes research in Finland. This symposium will serve to highlight both the 60th anniversary of the Foundation as well as the 15th Anniversary of the Finnish Diabetic Nephropathy Study. My sincere thanks go to all invited speakers and chairmen who, de- spite their busy schedules all agreed to come to Helsinki to share their knowledge and expertise with us. I am also indebted to all of you who accepted the invitation to take part in this event.
    [Show full text]
  • Dr. Martha Clokie Department of Infection, Immunity and Inflammation, University of Leicester, UK
    Graduate Schools Infection Immunity and Cancer, UniGe & UniL: CUS Biology & Medicine, CMU Seminars in Microbiology Monday, 8th December, 2014 Salle de séminaire 7172, CMU 11:00 – 12:00 Dr. Martha Clokie Department of Infection, Immunity and Inflammation, University of Leicester, UK The ecology, evolution and applications of Clostridium difficile bacteriophages Clostridia are Gram positive, anaerobic, sporulating bacteria of which some are important human pathogens. Clostridium difficile is present in the gut and is known to cause antibiotic treatment associated diarrhea. Bacteria have a core genome that is complemented by many genes that contribute to strain specific behavior and possibility to adapt to different environments. Some of these genes, which may encode virulence factors in pathogenic bacteria, are encoded by bacteriophages. The group of Martha Clokie has recently shown that a Clostridium phage encodes an agr-type quorum sensing system (QS), in which a secreted peptide represents the signaling molecule. It is suggested that the phage encoded agr system, which is missing the transcriptional activator AgrA, was taken from a bacterium and is transferred horizontally between Clostridia strains, thereby influencing the behavior of the lysogenic bacteria, though the interaction with resident agr quorum sensing systems in Clostridium. Hargreaves et al., Abundant and diverse clustered regularly interspaced short palindromic repeat spacers in Clostridium difficile strains and prophages target multiple phage types within this pathogen. MBio. 2014;5:e01045-13. Hargreaves et al., Bacteriophage behavioral ecology: How phages alter their bacterial host's habits. Bacteriophage. 2014 8;4:e29866. Hargreaves et al. What does the talking?: quorum sensing signalling genes discovered in a bacteriophage genome.
    [Show full text]
  • Translating Phage-Based Applications Into Clinically and Commercially
    SPEAKERS TO INCLUDE: Steffanie Strathdee Carl Merril Scott Stibitz & Tom Patterson CSO and Founder Microbiologist, Center for University of Adaptive Phage Biologics Evaluation and California San Diego Therapeutics Research FDA 29-30TH JANUARY 2019 | WASHINGTON D.C, USA Translating phage-based applications into clinically and commercially viable therapeutics Martha Clokie Biswajit Biswas Joe Campbell Professor of Chief, Division of Research Resources Microbiology Bacteriophage Science, Project Officer University of Biological Defense NIH (NIAID) Regulatory guidance to achieve clinical data from Cara Fiore, FDA Leicester Research Directorate US Naval Medical Research Center Strategies to access the market via the veterinary, personalized medicine and traditional pharmaceutical routes INSTITUTIONS PRESENT INCLUDE: Insights into investment drivers for phage therapy from NIH and Merck Facts on how to manufacture GMP phage Applications to overcome multi-drug resistance with combined approaches such as phage therapy and antibiotics www.phage-futures.com | +44 (0)20 3696 2920 | [email protected] WELCOME The Phage Futures Congress has the potential to act as a catalyst to further With antimicrobial resistance an ongoing worldwide issue, there is now a renewed interest cooperative and collaborative efforts in phage therapy as an alternative to antibiotics. There has been uncertainty as to whether to develop alternate Phage based approaches to phage therapy can be a commercially viable and FDA/EMA approved product. However, the the antibiotic
    [Show full text]
  • S41598-021-83773-1.Pdf
    www.nature.com/scientificreports OPEN Modelling the spatiotemporal complexity of interactions between pathogenic bacteria and a phage with a temperature‑dependent life cycle switch Halil I. Egilmez1, Andrew Yu. Morozov2,3* & Edouard E. Galyov2 We apply mathematical modelling to explore bacteria‑phage interaction mediated by condition‑ dependent lysogeny, where the type of the phage infection cycle (lytic or lysogenic) is determined by the ambient temperature. In a natural environment, daily and seasonal variations of the temperature cause a frequent switch between the two infection scenarios, making the bacteria‑phage interaction with condition‑dependent lysogeny highly complex. As a case study, we explore the natural control of the pathogenic bacteria Burkholderia pseudomallei by its dominant phage. B. pseudomallei is the causative agent of melioidosis, which is among the most fatal diseases in Southeast Asia and across the world. We assess the spatial aspect of B. pseudomallei‑phage interactions in soil, which has been so far overlooked in the literature, using the reaction‑difusion PDE‑based framework with external forcing through daily and seasonal parameter variation. Through extensive computer simulations for realistic biological parameters, we obtain results suggesting that phages may regulate B. pseudomallei numbers across seasons in endemic areas, and that the abundance of highly pathogenic phage‑free bacteria shows a clear annual cycle. The model predicts particularly dangerous soil layers characterised by high pathogen densities. Our fndings can potentially help refne melioidosis prevention and monitoring practices. Among major factors controlling bacterial numbers both in the wild and in artifcial environments are natural enemies known as bacteriophages or phages. Phages are viruses that can specifcally infect their host by attaching to particular bacterial receptors, injecting their genomic DNA (or RNA) into the host cell cytoplasm, and trigger- ing a process that can lead to phage replication or integration of phage genome into the host chromosome.
    [Show full text]
  • Ab Komplet 6.07.2018
    CONTENTS 1. Welcome addresses 2 2. Introduction 3 3. Acknowledgements 10 4. General information 11 5. Scientific program 16 6. Abstracts – oral presentations 27 7. Abstracts – poster sessions 99 8. Participants 419 1 EMBO Workshop Viruses of Microbes 2018 09 – 13 July 2018 | Wrocław, Poland 1. WELCOME ADDRESSES Welcome to the Viruses of Microbes 2018 EMBO Workshop! We are happy to welcome you to Wrocław for the 5th meeting of the Viruses of Microbes series. This series was launched in the year 2010 in Paris, and was continued in Brussels (2012), Zurich (2014), and Liverpool (2016). This year our meeting is co-organized by two partner institutions: the University of Wrocław and the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences. The conference venue (University of Wrocław, Uniwersytecka 7-10, Building D) is located in the heart of Wrocław, within the old, historic part of the city. This creates an opportunity to experience the over 1000-year history of the city, combined with its current positive energy. The Viruses of Microbes community is constantly growing. More and more researchers are joining it, and they represent more and more countries worldwide. Our goal for this meeting was to create a true global platform for networking and exchanging ideas. We are most happy to welcome representatives of so many countries and continents. To accommodate the diversity and expertise of the scientists and practitioners gathered by VoM2018, the leading theme of this conference is “Biodiversity and Future Application”. With the help of your contribution, this theme was developed into a program covering a wide range of topics with the strongest practical aspect.
    [Show full text]
  • Biological and Genomic Characterization of a Novel Jumbo Bacteriophage, Vb Vham Pir03 with Broad Host Lytic Activity Against Vibrio Harveyi
    pathogens Article Biological and Genomic Characterization of a Novel Jumbo Bacteriophage, vB_VhaM_pir03 with Broad Host Lytic Activity against Vibrio harveyi Gerald N. Misol, Jr. 1,2 , Constantina Kokkari 1 and Pantelis Katharios 1,* 1 Institute of Marine Biology, Biotechnology and Aquaculture, Hellenic Center for Marine Research, 71500 Heraklion, Crete, Greece; [email protected] (G.N.M.J.); [email protected] (C.K.) 2 Department of Biology, University of Crete, 71003 Heraklion, Crete, Greece * Correspondence: [email protected] Received: 18 October 2020; Accepted: 14 December 2020; Published: 15 December 2020 Abstract: Vibrio harveyi is a Gram-negative marine bacterium that causes major disease outbreaks and economic losses in aquaculture. Phage therapy has been considered as a potential alternative to antibiotics however, candidate bacteriophages require comprehensive characterization for a safe and practical phage therapy. In this work, a lytic novel jumbo bacteriophage, vB_VhaM_pir03 belonging to the Myoviridae family was isolated and characterized against V. harveyi type strain DSM19623. It had broad host lytic activity against 31 antibiotic-resistant strains of V. harveyi, V. alginolyticus, V. campbellii and V. owensii. Adsorption time of vB_VhaM_pir03 was determined at 6 min while the latent-phase was at 40 min and burst-size at 75 pfu/mL. vB_VhaM_pir03 was able to lyse several host strains at multiplicity-of-infections (MOI) 0.1 to 10. The genome of vB_VhaM_pir03 consists of 286,284 base pairs with 334 predicted open reading frames (ORFs). No virulence, antibiotic resistance, integrase encoding genes and transducing potential were detected. Phylogenetic and phylogenomic analysis showed that vB_VhaM_pir03 is a novel bacteriophage displaying the highest similarity to another jumbo phage, vB_BONAISHI infecting Vibrio coralliilyticus.
    [Show full text]
  • Bacteriophage Therapy: an Alternative to Antibiotics? an Interview Professor Clokie
    Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie Published on December 2, 2015 at 6:39 AM Interview conducted by April Cashin-Garbutt, MA (Cantab) Professor Clokie THOUGHT LEADERS SERIES ...insight from the world’s leading experts What is a bacteriophage and how many different types of phage exist? A phage is a virus that infects a bacterium. People often get very confused about what the difference is between a virus and a bacterium. A virus, like a bacterium, is also a microorganism, but unlike bacteria, it needs to have a host to be able to replicate and propagate. All bacteria have these natural viruses, just like we have viruses that make us sick and our children sick. All bacteria have their own sets of viruses, so they’re very specific. A virus, for example, that infects E. coli bacteria wouldn’t infect a different species of bacteria. Over 90% of all viruses found that infect bacteria fall into three families or ‘types’ of viruses, but for the thousands P Saved from URL: http://www.news-medical.net/news/20151202/Bacteriophage-therapy-an-alternative-to-antibiotics-An-interview-P 1 rofessor-Clokie.aspx /10 Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie of types of bacteria that exist, there are even more sub-types of viruses within these three families. The three major families of viruses are known as myoviruses, siphoviruses, podoviruses. They’re double-stranded DNA viruses and have different shapes. “Myo” means muscle and these viruses are have a long, contractile tail.
    [Show full text]
  • Bacteria Can Viral Infections As Well
    Paul Tyler, PSTT I BET YOU College Fellow, links DIDN’T KNOW... cutting-edge research with Bacteria get viral the principles of primary science infections as well [email protected] In 2016, a group of scientific experts from different fields Questions to ask children. came together to explore the most likely replacements What bacteria and viruses do you know? for antibiotics. They put together a list of 19 possible alternatives and narrowed it down to 10 that they felt What do bacteria and viruses do? were worth pursuing, and therefore funding. What is the difference between bacteria and virus? One of the possible alternatives considered is to use bacteriophages; viruses that attack and kill bacteria. This has been a common medical practice in some Eastern There are more than 30,000 species of bacteria defined European countries for nearly 100 years but research on Earth and they are found just about everywhere into bacteriophages in Western countries stopped when from the freezing Antarctic to the hottest volcanic antibiotics were discovered. environments. They are simple single celled organisms that reproduce by copying their DNA and then splitting One of the world’s leading experts on bacteriophages into two identical offspring cells (Figure 1). is Professor Martha Clokie, a microbiologist at the University of Leicester. Her research team are working Figure 1. Bacteria are types of single-celled organism. to understand the complex interactions between bacteria and bacteriophages in different environments. There is increasing evidence that viruses can control their bacterial hosts in a variety of ways, even in the human body.
    [Show full text]
  • Martha Clokie
    microbiologytoday vol35|aug08 quarterly magazine of the society for general microbiology life’s a gas microbes and oxygen … and it’s hydrogen methane: a natural gas microbial genetics of seaside smells toxic gases of the nitrogen cycle contents vol35(3) regular features 106 News 138 Schoolzone 146 Hot off the Press 114 Microshorts 142 Gradline 150 Going Public 136 Meetings 145 Addresses 154 Reviews other items 141 Obituary – Professor Norbert Pfennig articles 116 Microbes and oxygen 128 On the microbial genetics Martha Clokie of seaside smells A range of micro-organisms and even, Andy Johnston surprisingly, viruses are involved in oxygen DMS, responsible for the familiar aroma of the shore, is production on planet Earth. produced by complex microbial processes. 132 NO laughing matter: 120 Life’s a gas... and it’s the toxic gases of the hydrogen nitrogen cycle Mark D. Redwood & David J. Richardson, Lynne E. Macaskie Andrew J. Thomson & Some microbes gain energy by releasing hydrogen into the environment, a process which has many exciting Nicholas J. Watmough applications. Nitric oxide is an important part of the nitrogen cycle, but in some circumstances it can be a greenhouse gas. 124 Methane: a natural gas 156 Comment: Bad reporting in the media is hard to swallow James Chong Methane may be a greenhouse gas, but John Heritage conversely it also has great potential as a source Sometimes it can be a good thing that today’s newspaper is of green energy. tomorrow’s chip wrappings. Cover image A natural-gas fireball. Photos.com / Jupiter Images The views expressed Editor Dr Matt Hutchings––Editorial Board Dr Sue Assinder, Dr Paul Hoskisson, Professor Bert Rima––Managing Editor Janet Hurst––Assistant Editors Lucy Goodchild & Faye Stokes by contributors are not Editorial Assistant Yvonne Taylor––Design & Production Ian Atherton––Contributions are always welcome and should be addressed to the Editor c/o SGM HQ, Marlborough House, necessarily those of the Basingstoke Road, Spencers Wood, Reading RG7 1AG–Tel.
    [Show full text]
  • EASD2020 Finalprogramme.Pdf
    56TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES Content Page EASD . 4 Morgagni Prize . 10 General Information . 12 EASD Community Plaza . 15 Programme at a Glance . 20 EASD e-Learning . 28 European Diabetes Forum (EUDF) . 29 EFSD Mentorship Programme . 30 Tuesday, 22 September . 32 Claude Bernard Lecture . 32 Poster Event A . 41 Poster Event B . 42 Camillo Golgi Lecture . 50 Albert Renold Lecture . 52 Wednesday, 23 September . 54 Poster Event C . 64 Poster Event D . 65 Diabetes Prize for Excellence Lecture . 72 Thursday, 24 September . 77 Rising Star Symposium . 80 Poster Event E . 90 Poster Event F . 91 Minkowski Lecture . 98 Friday, 25 September . 102 Posters . 119 Index of Presenting Authors . 230 Index of Symposium Speakers . 242 European Foundation for the Study of Diabetes (EFSD) . 244 Symposia on the occasion of the 56th EASD Annual Meeting . 248 Industry Symposia and Meet the Expert Sessions on the occasion of the 56th EASD Annual Meeting (organised by INTERPLAN) . 263 57th EASD Annual Meeting . 310 DEAR MEMBERS AND GUESTS, It is my great honour and pleasure to welcome you to the 56th Annual Meeting of the European Association for the Study of Diabetes, which will take place – due to the severe global impact of the COVID-19 pandemic – as an innovative Virtual Meeting from 21 to 25 September 2020. EASD We have developed a virtual experience using the latest technology to connect the global diabetes community, share ground-breaking diabetes science and research, and to provide educational opportunities that
    [Show full text]
  • Biological Sciences
    Module Specification BS1030 Biochemistry Academic Year: 2017/8 Student Workload (hours) Module Level: Year 1 Lectures 50 Scheme: UG Seminars Department: Biological Sciences Practical Classes & Workshops 30 Credits: 30 Tutorials 6 Fieldwork Project Supervision Guided Independent Study 214 Demonstration Supervised time in studio/workshop Work Based Learning Placement Year Abroad Total Module Hours 300 Period: Semester 1 Occurence: E Coordinator: Mark Leyland Mark Scheme: UG Pass for Credit No. Assessment Description Weight % Qual Mark Exam Hours Ass't Group Alt Reass't 001 Practical report 15 002 Report 15 003 Online assessment 10 004 Examination (Final) 60 2 Intended Learning Outcomes By the end of this module students should be able to: Explain the basic chemical principles that underpin biochemistry Describe the structures of biological macromolecules and their components Discuss the principles and mechanisms of information transfer from DNA to proteins Explain the basic principles of enzyme catalysis Describe the relationship between structure and function for some proteins Outline the key features of biological membranes Describe the key metabolic processes within a cell and recognize the importance of regulation Combine facts and ideas in clear and concise written and oral communications Demonstrate basic biochemical laboratory skills using safe laboratory practice Analyse experimental results using core data-handling skills Teaching and Learning Methods Lectures, practicals, work sessions and tutorials. Assessment Methods Laboratory
    [Show full text]